From invention to adoption: the work between
Invention creates a possibility. Adoption requires authority, evidence, implementation, review and a reason for people to change what they do.
Read articleNEUVIOR insights
Insights and analysis
Read deep analysis on medicines implementation, governed technology, best value biological medicines, pharmaceutical infrastructure and the founder thesis connecting PHARMORIS with NEUVIOR’s wider direction.
What feasibility support should actually buy
Support matters when it converts expensive uncertainty into a clearer product, technical, commercial or stop decision.
Read articleWhat feasibility research must prove
Feasibility becomes useful when the question, constraints, evidence threshold and stop or continue decision are explicit before the work begins.
Read articleA trade deal is not a patient pathway
A trade agreement can change the commercial and policy context. The value depends on whether each implementation gate has evidence, ownership and a route to learning.
Read articleThe 30p rule: how discipline builds trust
The smallest amount can reveal whether a business understands its margins, respects its records and keeps the promises hidden inside the numbers.
Read articleWhen three medicines numbers can all be right
Before you choose the number that supports a decision, make the population, price basis, time window and source visible.
Read articleAfter NICE: making medicines access operational
A recommendation can clarify what should be available. You still need an accountable route from evidence to a local decision, delivery and review.
Read articleFrom hyperfocus to governed execution
If your mind sees the whole system at once, the next challenge is making that insight legible, owned and repeatable for everyone who must act on it.
Read articleFrom medicines intelligence to medicines development: the founder thesis connecting NEUVIOR and VARUNÉ Labs
Varun Sharma explains how medicines intelligence, formulation, development and future manufacturing can inform one founder thesis while each company, concept and capability retains its true operating status.
Read articleBest value biological medicines are the clearest near term medicines productivity play in the NHS
If NHS leaders are looking for a near term medicines productivity play with a strong policy tailwind, best value biological medicines should be near the top of the list.
Read articleNHS digital programmes do not fail on dashboards. They fail on deployment
The NHS does not lack medicines dashboards. It lacks enough tools that turn those signals into action. That distinction matters because many digital programmes in medicines still behave as though visibility is the scarce resource.
Read articleThe quarterly medicines leakage report every ICB should want in 2026/27
If strategic commissioning is going to mean anything in 2026/27, it has to change how integrated care boards manage medicines value.
Read articleThe NHS has not finished the generic job
A familiar line turns up whenever medicines productivity is discussed in the NHS: generic prescribing has already been done. The easy gains have gone. We need to look elsewhere.
Read articleFrom pilot theatre to financial grip: how NHS CFOs should evaluate AI in medicines optimisation
NHS finance leaders do not need another AI pitch. They need a disciplined way to decide whether a technology can release value within the financial rules they are already being held to.
Read article